GLOBALPHARMA, a leading pharmaceutical company in the UAE and a subsidiary of Dubai Investments PJSC, has trained its sights on regions far beyond the Middle East, Africa and the Far East where it is already a recognised player having earned a reputation for quality and reliability.
“Building on this foundation, Globalpharma intends to explore opportunities in European and North American markets, expand production into a wider therapeutic range and introduce innovative and more effective drug delivery systems,” a company statement said.
“The company has built an enviable reputation of being reliable and quality conscious as well as ethical and socially responsible. It has achieved its status in a highly competitive market crowded with multinational conglomerates,” it added.
Globalpharma has its production facilities at Dubai Investment Park. Annual production capacity is 300 million tablets, 150 million capsules and over seven million litres of dry suspension and liquids comprising antibiotics, cardiovasculars, anti-ulcerants, analgesics, NSAIDS, food supplements, vitamins, anti-diabetics, respiratory products and anti-histamine formulations.
The company adheres to international standards of current good manufacturing practices (CGMP) including those set by the US Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) UK. The facilities and processes are also approved by the health authorities in all markets where Globalpharma supplies its products.
Pursuing its export goals, the company exhibited a selection of new products including the cardio-metabolic range of medicines as also its branded generics at the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (Duphat) 2014 that was held recently. Its new range on show at the event included antibiotics and anti-asthmatic medicines.
Jamil Akhtar, general manager at Globalpharma, said Duphat provided his company with the right platform to exhibit its capabilities – especially in the new formulations it has devised, besides exploring new opportunities and forging synergies with global pharmaceutical companies eyeing the Middle East market.
Starting its commercial operations in 2003, Globalpharma has emerged as a quality-centric and reliable player in the regional pharmaceutical market. The company markets its pharmaceutical products in more than 20 countries across the Middle East, Africa and Far East.